Clinical Trials Insights
Clinical Trials Insights
Racura Oncology cleared to escalate RC220 to 100 mg/m2 in phase 1 trial in EGFR-mutant non-small cell lung cancer
The Safety Review Committee (SRC) for a clinical trial has cleared Racura Oncology’s lead oncology drug, RC220 to escalate to the next planned dose...
Clinical Trials Insights
Immorta Bio pioneers AI-designed senolytic immunotherapy targeting diseases of aging
Immorta Bio, a biotechnology company pioneering therapies targeting fundamental mechanisms of aging, has completed preclinical studies for SenoMune-0257, an AI-designed peptide immunotherapy developed to...
Clinical Trials Insights
Pfizer’s Litfulo significantly improved facial and total body repigmentation in patients with nonsegmental vitiligo
Pfizer has presented results from two phase 3 trials evaluating the efficacy and safety of Litfulo (ritlecitinib) as a once-daily oral treatment across a...
Clinical Trials Insights
Novo Nordisk’s Wegovy (semaglutide) reduced liver fat to normal levels in nine out of 10 adults with obesity and excess liver fat – EASD2026
Novo Nordisk has presented post hoc analysis of data from a trial sub-population with 55 participants, showing that Wegovy (pooled semaglutide 7.2 and 2.4...
Clinical Trials Insights
Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new phase 3 trial, alongside significant improvements in glycaemic control in people with obesity...
Boehringer Ingelheim has announced positive results from a phase 3 trial, which investigates the glucagon/GLP-1 receptor dual agonist survodutide (BI 456906) in adults living...
Clinical Trials Insights
Biogen’s Litifilimab demonstrates rapid and durable efficacy in new 52-week phase 2 data from ongoing phase 2/3 study, reinforcing its potential as a first-in-class...
Biogen has announced 52-week results from the phase 2 part of the ongoing phase 2/3 study of litifilimab in people living with cutaneous lupus...
Clinical Trials Insights
Johnson & Johnson announces new Icotyde (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through two-years, affirming its use as a powerful first...
Johnson & Johnson has announced new two-year data from a phase 3 study demonstrating the positive impact of Icotyde (icotrokinra) on high-impact plaque psoriasis...
Clinical Trials Insights
Anixa Biosciences announces first case of stable disease for three months in ovarian cancer CAR-T clinical trial
Anixa Biosciences, a biotechnology company focused on the treatment and prevention of cancer, has announced that a patient in its ongoing phase 1, dose-escalating,...
- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -
